Related Experiment Videos
[Current therapeutic possibilities in chronic inflammatory intestinal diseases]
1Klinik und Poliklinik für Innere Medizin I, Universität Regensburg.
Praxis
|January 10, 1995
Summary
This review covers chronic inflammatory bowel disease treatments, focusing on steroids for active Crohn's disease and ulcerative colitis. It also discusses 5-aminosalicylic acid and novel nonsystemic steroid developments.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Context:
- Chronic inflammatory bowel disease (IBD) management involves distinct strategies for active disease, chronic active states, and relapse prevention.
- Current therapeutic approaches for IBD, including Crohn's disease (CD) and ulcerative colitis (UC), rely on established pharmacological and surgical interventions.
Purpose:
- To outline the current treatment paradigms for chronic inflammatory bowel disease, encompassing active disease management, chronic active disease strategies, and relapse prevention.
- To highlight the role of corticosteroids, 5-aminosalicylic acid, immunosuppressive agents, and surgical interventions in managing IBD.
- To introduce emerging developments in IBD therapy, particularly nonsystemic steroids.
Summary:
- Corticosteroids are crucial for treating active Crohn's disease and ulcerative colitis.
- 5-aminosalicylic acid is utilized for mild to moderate ulcerative colitis and for preventing IBD relapse.
- Immunosuppressive drugs are key for chronic active Crohn's disease, whereas surgery is significant for ulcerative colitis management.
Impact:
- Provides a comprehensive overview of current IBD treatment strategies.
- Informs clinicians about the established roles of various therapeutic agents in IBD management.
- Highlights the direction of new research in nonsystemic steroid development for IBD.